

6

Ms. Jane Axelrad, Associate Director for Policy  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Woodmont Building, Room 6027  
Rockville, Maryland 20852

Dear Ms. Axelrad,

As you may recall, I presented some material pertaining to the use of DMPS (dimercapto propane sulfonate) to the Pharmacy Compounding Advisory Committee on July 13, 2000. After my presentation, there was some indication that no MedWatch reports had been received regarding this drug.

I thought that I had filed a MedWatch report on August 14, 1998. However, it seems that the report taken from me by FDA investigator Joseph Despina was actually an investigative report which he subsequently filed with Dr. Tony Carreras of the Division of Scientific Investigations. My understanding is that the subsequent investigation was dropped after it was discovered that DMPS was nominated for the Bulk Drug List.

I have today, therefore, filed a MedWatch report regarding my experience with this drug. Because there was some discussion that the MedWatch reporting system is not equipped for handling reports of adverse events for unapproved drugs, I am sending a copy to you to ensure that it is officially recorded.

I hope that the FDA is reviewing the appropriateness of this drug for inclusion on the Bulk Drug List. If I can be of assistance in any way, please do not hesitate to contact me. Thank you for your time and attention to this important matter.

Sincerely,

98D-0272

C14

THE FDA MEDICAL PRODUCTS REPORTING PROGRAM

Form Approved: GSA No. 0075-0179 E23 May 1973  
Use GSA Standard 49 104-000

FDA USC OFF

**TRAVELER'S CHECKS**

Page        of       

Submission of a report does not constitute an admission that medical personnel or the product caused or contributed to the event.